Xcout Intel
Aspen Neuroscience competitors & alternatives
The 12 closest competitors and alternatives to Aspen Neuroscience among biotechnology companies — ranked by similarity to what Aspen Neuroscience actually does, not by market-cap band.
Subscribe to see Aspen Neuroscience’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aspen Neuroscience
Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company headquartered in San Diego, California. The company focuses on developing personalized autologous cell therapies for neurodegenerative diseases.
Aspen Neuroscience at a glance
Aspen Neuroscience is a biotechnology company headquartered in United States. It has raised at least $262.5M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series C, raised $115M in November 2025. Xcout tracks 12 named people at Aspen Neuroscience, including Damien McDevitt (President and Chief Executive Officer).
Aspen Neuroscience leadership
- Damien McDevittPresident and Chief Executive Officer
- Dalen MeeterChief Financial Officer
- Kim RaineriChief Technology Officer
- Ana SousaChief Regulatory Officer
- Lisa Johnson-PrattChief Commercial Officer
- Revati ShreeniwasChief Medical Officer
6 more named people on record for Aspen Neuroscience, with roles, board committees and tenure — see the full roster →
Aspen Neuroscience funding rounds
At least $262.5M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $115M | 13 named | |
| — | $147.5M | 14 named | |
| — | Undisclosed | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Aspen Neuroscience competitors
Ranked by semantic similarity — how close each company is to Aspen Neuroscience by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York City, New York, focused on developing gene therapies for patients with neurodegenerative diseases.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Biotech
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Biotech
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Biotech
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Similar biotechnology company
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Similar biotechnology company
AskBio is a clinical-stage gene therapy company that develops adeno-associated virus (AAV) gene therapies to treat genetic and complex disorders. The company focuses on advancing genetic medicine through its proprietary technology platforms, manufacturing processes, and clinical trials.
Biotech
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Similar biotechnology company
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotech
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Similar biotechnology company
Vico Therapeutics is a neurology genetic medicine and biotechnology company pioneering targeted treatments for devastating disorders from its location at the BioScience Park.
Similar biotechnology company
Persephone Biosciences, Inc. is a synthetic biology company headquartered in San Diego, California. The company reimagines patient and infant health by developing clinically researched synbiotics derived from microbiome research.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aspen Neuroscience and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aspen Neuroscienceand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →